A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism by unknown
REVIEW Open Access
A review on effects of conjugated linoleic
fatty acid (CLA) upon body composition
and energetic metabolism
Tatiana Ederich Lehnen1,4, Marcondes Ramos da Silva2, Augusto Camacho1,2, Aline Marcadenti2,3
and Alexandre Machado Lehnen1,2*
Abstract
Conjugated linoleic acid (CLA) is highly found in fats from ruminants and it appears to favorably modify the body
composition and cardiometabolic risk factors. The capacity of CLA to reduce the body fat levels as well as its benefic
actions on glycemic profile, atherosclerosis and cancer has already been proved in experimental models. Furthermore,
CLA supplementation may modulate the immune function, help re-synthetize of glycogen and potentiate the bone
mineralization. CLA supplementation also could increase the lipolysis and reduce the accumulation of fatty acids on
the adipose tissue; the putative mechanisms involved may be its action in reducing the lipase lipoprotein activity
and to increase the carnitine-palmitoil-transferase-1 (CAT-1) activity, its interaction with PPARγ, and to raise the
expression of UCP-1. Although studies made in human have shown some benefits of CLA supplementation as
the weight loss, the results are still discordant. Moreover, some have shown adverse effects, such as negative
effects on glucose metabolism and lipid profile. The purpose of this article is to review the available data
regarding the benefits of CLA on the energetic metabolism and body composition, emphasizing action
mechanisms.
Introduction
Although many research studies are inconclusive about
functional foods, their benefits to health have often been
discussed, calling the attention of the scientific commu-
nity [1–3]. Thus, several studies were performed claim-
ing that functional foods are essential for health and
have helped reduce the risk of developing various
chronic diseases [4–6]. This functional property con-
cerns the metabolic or physiological role played by the
nutrient or non-nutrient in growth, development, matur-
ity and other normal functions of the human organism.
However, studies on nutraceutics (foods with a medi-
cinal function) lack further explanation, especially re-
garding the associated protective effects. The doses
indicated generate doubts that these effects will be
achieved, and also regarding the possible adverse effects
of their long term use [1–3].
Several classes of substance which are naturally
present in foods or produced by food technology have
functional properties. One of these substances is conju-
gated linoleic acid (CLA) - a fatty acid which presents a
linoleic acid isomer (C18:2, n-6) and has been consid-
ered an antiobesity agent, and can be useful in the
weight reduction process [7]. Although the initial re-
sults were found only in an animal model [8, 9], more
recent research on humans suggests that CLA would
act to reduce adiposity through modulating properties
in the lipid metabolism [10, 11]. However, doubts re-
main as to the action mechanisms of CLA in adipo-
cytes, leading to the reduction of body fat and,
especially, the safety of supplementation of this
compound.
Therefore, the purpose of this review is to describe the
effect of CLA supplementation on body composition,
particularly on the reduction of adiposity, focusing on
possible action mechanisms.* Correspondence: amlehnen@gmail.com
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Conjugated linoleic acid
Conjugated linoleic acid (CLA) is a term that describes a
group of fatty acids with 18 atoms of carbon, and the geo-
metric isomers consist of linoleic acid [12]. This is a com-
mon name given to a group of position isomers with two
double bonds separated by a methylene group [7, 13]. This
conjugation of the double bond is generally in positions 9
and 11 or 10 and 12, and may be a cis or trans configur-
ation (Fig. 1).
CLA is produced naturally in the digestive tract of ru-
minants such as cattle, goats, sheep, buffalo, and to a
lesser degree in pigs, chickens and turkeys, and the syn-
thesis occur due to fermentative bacteria, Butyrivibrio
Fibrisolvens, which isomerize the linoleic acid in CLA or
by synthesis via α9-desaturase of 11-trans octadecanoic
acid [14]. The fat in beef contains about 1.7 to 10.8 mg
CLA/g of fat with 9-cis and 11-trans isomers. It is also
found in dairy products (milks and derivatives) [6].
CLA can be obtained by means of enzyme α9-
desaturase which promotes the desaturation of the 11-
trans octadecanoic acid. Several different isomers of CLA
such as 11-trans and 9-cis are the best known because
they are found in food [7, 12]. It is also possible to obtain
CLA in an industrial form, through the partial hydrogen-
ation of linoleic acid or by thermal treatments, aiming to
produce a compound with maximum biological activity
and with a defined chemical composition [10].
CLA has a major role in the lipid metabolism, espe-
cially as regards the oxidative cellular system, which ex-
plains many physiological properties of fatty acids. Their
action on the lipid metabolism is associated with the in-
hibition of the entry of glucose into the adipocytes, and
may lead to changes in the insulin metabolism and cause
situations of hyperinsulinemia, as well as the increase of
inflammatory markers [15, 16].
There are many investigations to evaluate the influ-
ences of CLA on the energetic metabolism, promoting
significant changes in the lipid metabolism and in body
composition [9–11, 17–20]. As a result, some effects can
be cited such as: reduction of body fat, improved insulin
resistance, antithrombogenic and anticarcinogenic ef-
fects, reduction of atherosclerosis, improved lipid profile,
modulation of the immune system and stimulation of
bone mineralization, and also reduced blood glucose.
The most studied CLA supplementation effect is its cap-
acity to alter the body composition, promoting an in-
crease in lean mass and reduction of the fatty mass.
Putative mechanisms of action
The possible action mechanisms which show that CLA
can alter the body composition involve metabolic
changes that favor the reduction of the lipogenesis and
the potentiation of lipolysis, accompanied by the oxida-
tion of fatty acid in the skeletal muscle, due to increased
carnitine palmitoil-transferase-1 activity and action, or
possibly because of adipocyte differentiation inhibition
[7]. Therefore, researchers have evaluated the action of
CLA supplementation on the lipid and hormone profile,
and the activity of the enzymes involved in the oxidation
process [21].
Studies have demonstrated that isomers 10-trans and
12-cis, differently from the 9-cis 11-trans of CLA, increase
lipolysis significantly in the human adipocytes, and also
have the function of diminishing the synthesis of fatty
acids [15]. This would explain, in part, the possible action
mechanisms of CLA on the body composition. Although
various studies were in vitro, the metabolic hypotheses to
explain the body fat reducing action of CLA began based
on control of the expression of genes involved in the dif-
ferentiation of pre-adipocytes into mature adipocytes, in
other words, the expression of these genes would result in
reducing lipogenesis [22, 23].
In turn, the peroxisome proliferator-activated recep-
tors (PPARs) are nuclear transcription factors that play a
central role in the storage and catabolism of fatty acids
(FA). They are part of a class of nuclear receptors that
belong to the family of the nuclear receptor of the ster-
oid, retinoid and thyroid receptors. Three isoforms of
the nuclear receptor have already been identified,
PPARα, PPARβ and PPARγ. PPARα and β are involved
in the lipid metabolism (especially the proteins related
to FA oxidation) and glucose, and PPARγ is involved in
adipocyte differentiation [24, 25].
Fig. 1 Isomer structure. (1) represents CLA 10-trans and 12-cis;
(2) indicate CLA 9-cis and 11-trans; (3) C18:2 9-cis and 12-cis
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Figure 2 shows the activation mechanism and re-
quires the release of the co-repressor complex (histone
deacetylase activity) by a binder, and the recruitment of
the co-activator complex (acetyltransferase activity).
The activated PPAR:RxR complex binds to the elements
that are responsive to peroxisome proliferators (PPRE),
producing changes in the chromatin structure, giving
rise to a transcriptionally competent structure. Hence,
it seems that the CLA interacts with the Co-activator
complex PPAR increasing the gene transcription related
to the differentiation of adipocytes, lipolysis (β-oxidation),
mitochondrial biogenesis and insulin sensitivity, and col-
lectively, it is related to the weight loss effect [24].
The effects of CLA in lipid and glucose metabolism on
body composition are mediated by the activation or in-
hibition of the PPARs, especially PPARγ. The inhibition
of PPARγ by CLA (isomer 10-trans, 12-cis) leads to the
reduction of body fat by modulation of the gene expres-
sion in the sense that it inhibits cell differentiation and
alters the activity of proteins involved in lipogenesis and
in lipolysis [26]. Evidence suggests that the activation of
PPARγ can diminish the progression of atherosclerosis
and increase sensitivity to insulin, and may be a poten-
tial therapeutic target for the treatment of various dis-
eases, including diabetes mellitus type 2 (DM2) and
dyslipidemia.
In adipocytes, PPARγ regulates the expression of genes
involved in the lipid metabolism, including acyl CoA-
synthetase and lipoprotein lipase (LPL). The expression
of the transport protein of fatty acids involved in the up-
take of lipids by the adipocytes is also controlled by
PPARγ [25].
The reduction of body fat occurs not due to the reduc-
tion in the number of adipocytes but rather by the re-
duction of their size. Considering that the size of the
adipose cells is directly elated to the triglyceride content
inside the cells, its reduction results in a smaller cell
size. The increased β-oxidation of mitochondrial fatty
acids induced by CLA may be responsible for the
reduction of triacylglycerol synthesis, not depositing
them in the adipocyte, but reducing their size [8].
The fatty acid is transported into the mitochondria by
the carnitine-palmitoil-transferase (CPT) complex. Three
enzymatic components are involved: CPT-1, CPT-2 and
carnitine acylcarnitine translocase (CATC) [27]. The fatty
acids are activated by the acyl-CoA synthetase enzyme
forming an activated complex (fatty acyl-CoA), with the
carnitine-palmitoil-transferase (CPT-1) enzyme. This com-
plex penetrates the mitochondrial membrane and reaches
the intermembrane space. Acyl-CoA is regenerated with
the release of carnitine in the CPT-2 reaction. Once it
reaches the mitochondrial matrix, the long chain fatty acid
(LCFA) is oxidized to generate adenosine triphosphate
(ATP) through the β-oxidation of the fatty acids [27]. CLA
supplementation would increase the concentration and ac-
tivity of CPT-1. Thus, collectively, the increased lipolysis,
the reduction of lipase lipoprotein activity and increased
carnitine-palmitoil-transferase-1 (CAT-1) activity lead to
the reduction of the accumulation of fatty acids in the adi-
pose and muscle tissues. These action mechanisms are
those most discussed by the researchers [8]. Inside the
mitochondria the fatty acids are oxidized by β–oxidation
reactions and Cycle of Krebs (CK), releasing the H+ and e-
which are carried (NADH+2 and FADH2) to the respiratory
chain (1). The gradient of H+ and e- between the inter-
membrane space and the matrix determines its return
passing by the ATP synthase protein (2) with a synthesis of
ATP (coupled reaction) or by the uncoupling protein (3)
producing heat.
However, the rationale that CLA stimulates lipolysis
only by increasing CPT-1 is valid (and limited) for situa-
tions in which β-oxidation (capacity to generate ATP
through the successive break down of fatty acid carbon)
is more efficient than the transport of the fatty acyl-CoA
complex to the mitochondrial matrix. In this way it is
possible and logical to say that CLA supplementation (in-
creasing CPT-1 concentration and activation) would only
have a potential effect on physically active individuals,
Fig. 2 Mechanism for transcriptional activation by PPAR. Panel a shows the inactivated state, without gene transcriptional of any target genes.
Panel b shows the activation of PPAR by PPAR ligands and RXR by 9-cis-RA (9-cis-retinoic acid), thereby stimulating target genes transcription
by binding to specific DNA sequence (peroxisome proliferators – PPRE) leading to increased β-oxidation, mitochondrial biogenesis and
insulin sensitivity
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particularly for those whose β-oxidation is more efficient
than the transport of fatty acid itself to the mitochondrial
matrix.
On the other hand, weight loss with CLA supplemen-
tation could be explained by its association with the
uncoupling protein of the respiratory chain (UCP), po-
tentiating the β-oxidation capacity [28]. The respiratory
chain or electron transport chain is formed by a series of
transport compounds located in the inner membrane of
the mitochondria. The last of these of these compounds
is called cytochrome-oxidase, the only one that presents
all necessary conditions to deliver electrons directly to
the O2. However, not all of the energy contained in the
electrons will be contained in the ATP, since part of it
evolves as heat to maintain the spontaneity of the succes-
sive transfers. As the electrons flow through the respira-
tory chain, they lose their free energy. Part of this energy
can be picked up and stored to produce ATP from ADP
and inorganic phosphate. The rest of the free energy,
which is not taken up for ATP re-synthesis, is released in
the form of heat, increasing UCP activity [29, 30].
UCPs are proteins found in the inner mitochondrial
membrane that allow proton flow from the intermem-
brane space to the mitochondrial matrix. However, the
return of protons to the mitochondrial matrix does not
lead to energy storage in the form of ATP thereby re-
leasing heat. UCP-1, also known as thermogenin, often
speeds up the proton return to the mitochondrial matrix
so that energy from Krebs cycle, originated from the oxi-
dation of energetic substrates (including lipids), is lost in
the form of heat (which can lead to weight loss if this
UCP is stimulated) [31].
UCPs can be subdivided into UCP-1, UCP-2 and UCP-
3. They differ in their distribution among tissues and
possible function. UCP1 is exclusively expressed in
brown adipose tissue; UCP3 is expressed in muscle and
a number of other tissues; and UCP2 is expressed in a
variety of tissues including white adipose tissue (WAT)
and is the most highly expressed UCP [32]. These pro-
teins can exert a thermogenic effect and are capable of
depleting the proton gradient, but their functions are
not yet completely clear [13, 26, 31].
UCP-1 is responsible for lipid oxidation and heat pro-
duction in brown adipose tissue (abundant in hiberna-
ting animals). Human adults have higher levels of white
adipose tissue and have UCP-2 and UCP-3, which ap-
pears to be related to heat generation. Other UCPs
(UCP-4, for instance) are also being investigated [31].
The administration of thyroid hormones leads to re-
spiratory chain uncoupling, which might be explained by
an increase in UCPs [33]. Moreover, lipolysis resulting
from fasting appears to stimulate UCPs, and the inter-
action of fatty acids with PPAR seems to increase the ex-
pression of UCPs [34].
Supplementation with a CLA mixture or 10,12 CLA in
rodents has been shown to induce UCP2 transcription
in WAT [32, 35, 36], but whether it plays a role in en-
ergy dissipation is unclear. It would appear that CLA in-
teracts with PPARγ, increases CTP-1 and expression of
UCP-1 resulting in greater capacity for lipolysis and fat
mass weight reduction [28].
Evidences from experimental animal
According to Gaze et al. [37], the effect of CLA is not the
same in all animal models. Rats supplemented with 0.5 %
of CLA, for instance, presented a small, but fast (7 days)
reduction of adipose tissue, compared to mice [37].
Botelho [8] evaluated the effects of supplementation
with CLA on the body composition of healthy Wistar
rats supplemented for 3 weeks with CLA at the concen-
trations of 1 %, 2 % and 4 % on the daily consumption
of the diet + control group (2 % linoleic acid). At the end
of the period, the groups that were supplemented at a
concentration of 2 % and 4 % with CLA presented a
greater body fat reduction compared to the control
group [8].
Other researchers evaluated coconut oil, maize oil and
CLA. In this study 28 rats were allocated to 4 different
diets: supplementation with coconut oil, coconut oil and
CLA, maize oil and maize oil and CLA. After 28 days,
total cholesterol, HDL–c and triglycerides were evalu-
ated. It was found that the triglycerides diminished in
the diet supplemented with coconut oil and CLA, and
HDL-c diminished with the maize oil diet. The total
cholesterol concentrations were lowest in the rats on the
coconut oil and CLA diet, but not in the diet with maize
oil and CLA. This study suggests that the CLA might di-
minish adiposity and improve the lipid profile under
some conditions [9].
Evidences from human studies
In recent years, CLA supplementation has also been
used in sports, aiming to reduce body fat and possibly
improve performance [38]. Furthermore, other supposed
benefits include improved lipid profile [39] and/or anti-
inflammatory effects [40] that can reduce oxidative
stress [41] and ameliorate insulin signaling [42], among
others. Collectively, these mechanisms improve body
composition and energetic metabolism. Table 1 shows
16 randomized clinical trials (RCT) using CLA as inter-
vention (last 5 years, Pubmed database) on putative ben-
efits. It is possible to see that 9 RCTs, from a total of 16,
showed no benefit on aspects related to CLA supple-
mentation. In addition, the studies shown in Table 1,
other evidence from human studies are shown below.
Few studies have evaluated changes in body compos-
ition with the use of CLA alone or in combination with
physical exercise in humans. Blankson et al. [10] showed
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Table 1 Randomized clinical trials using CLA as intervention on putative benefits
Author Sampling Study design Intervention Results
BACHMAIR et al., 2015 [55] Forty-three healthy adults at




Sample received 4 g/day of CLA80:20
or placebo for two weeks
No clear evidence was found for inhibition
or activation of platelet function as well as
inflammation by CLA80:20 in a low to
moderate cardiovascular risk group.




Randomly assigned to either a CLA
(Clarinol A-80; n = 18) or placebo
(PLA; sunflower oil; n = 16) group
Prior to and following 6 weeks of
aerobic training (50 % VO2peak for
30 min, twice per week) and
supplementation (5.63 g of total
CLA isomers [of which 2.67 g was
9-cis, 11-trans and 2.67 g was
10-trans, 12-cis] or 7.35 g high
oleic sunflower oil per day)
Serum triacylglycerol concentrations were
lower (p < 0.05) in the CLA than the PLA
group. For VO2peak and glucose, there
were group × time interactions (p < 0.05).
However, post-hoc statistical tests did not
reveal any differences between the CLA
and PLA groups.




Randomly assigned to either a CLA
(Clarinol A-80; n = 17) or placebo
(PLA; sunflower oil; n = 16) group.
Before and after 6 weeks of aerobic
training (50 % VO2peak for 30 min,
twice per week) and supplementation
(8 ml CLA or PLA per day), each subject
completed an incremental cycle
ergometer test, maximal number of
sit-ups in 1 min, and the standing
long jump
There were no differences between the CLA
and PLA groups for the analysis of covariance-
adjusted post-test mean values for physical
working capacity, sit-ups, or standing long
jump. The physical working capacity increased
from pre- to post-training in the CLA (p = 0.003)
and PLA (p = 0.003) groups. There were no
differences from pre- to post-training for sit-ups
and standing long jump in either the CLA or
PLA groups. There was no effect of CLA on
physical working capacity, maximum number
of sit-ups or standing long jump.
ARYAEIAN et al., 2014 [58] Seventy eight adults with
active rheumatoid arthritis
Double-blind clinical trial Four groups receiving one of the
following daily supplement for 3 months;
group C: 2.5 g CLAs, group E: 400 mg
Vitamin E, group CE: CLAs plus Vitamin E,
group P: Placebo. Cytokines, matrix
metalloproteinase (MMP-3) and citrullinated
antibody (CCP-A)
Co-supplementation CLAs and Vitamin E may
be effective in the level of inflammatory
markers in rheumatoid arthritis patients.
EFTEKHARI et al., 2014 [59] Ninety atherosclerotic patients clinical randomized trial Patients were classified into 3 groups
receiving 3 g/d CLA or 1 920 mg/d
ω3 or placebo for 2 months.
Although CLA did not appear to have a
significant effect on triglycerides, ω3
supplementation significantly reduced
triglycerides level. Consumption of CLA
and ω3 supplementation did not significantly








CLA group (n = 16), receiving 3 g CLA/d,
and placebo group (n = 18) receiving
placebo capsules (sunflower oil) for
6 weeks
CLA supplementation improved inflammatory
factors, MMP-2, and MMP-9 as biomarkers of
angiogenesis and tumor invasion. It seems
that CLA may provide new complementary
treatment by reducing tumor invasion and
















Table 1 Randomized clinical trials using CLA as intervention on putative benefits (Continued)
PENETO et al., 2013 [61] Twenty nine healthy adult
volunteers (nineteen women and
ten men, aged twenty two to
thirty six years)
Double-blind clinical trial CLA depletion was achieved through
an 8-week period of restricted dairy
fat intake (depletion phase; CLA intake
was 5.2 ± 5.8 mg/day), followed by an
8-week period in which individuals
consumed 20 g/day of butter naturally
enriched with 9-cis, 11-trans CLA
(repletion phase; CLA intake of 1020 ± 167
mg/day)
The intake of a 9-cis, 11-trans CLA-enriched
butter by normal-weight subjects induces
beneficial changes in immune modulators
associated with sub-clinical inflammation
in overweight individuals.






Participants received strawberry jam
enriched or not with microencapsulated
CLA (3 g/day) as a mixture of 38.57 % 9-cis,
11-trans, and 39.76 % 10-trans, 12-cis CLA
isomers associated with a hypocaloric
diet for 90 days
There were no significant effects of CLA on
the lipid profile or blood pressure. Mean
plasma insulin concentrations were significantly
lower in women supplemented with CLA,
did not alter the waist circumference, but
there was a reduction in body fat mass
detected after 30 days, and had a reduced
waist circumference




Volunteers were randomly divided into
CLA and placebo supplementation
groups; both groups underwent daily
supplementation of either 3 g CLA or
3 g placebo for 30 days and performed
exercise on a bicycle ergometer 3 times
per week
CLA is not more effective than exercise alone.








Volunteers consumed 200 ml/day of
skimmed milk with 3 g of CLAs or 3 g
olive oil (placebo).
The consumption of skimmed milk enriched
with 3 g of a 1:1 mixture of 9-cis, 11-trans and
10-trans, 12-cis for 24 weeks led to a decrease
in body weight and total fat mass in healthy,
overweight subjects who maintained habitual
diets and exercise patterns. No adverse effects
were observed
ENGBERIN et al. 2012 [65] Sixty-one healthy volunteers Double-blind, placebo
controlled study
The diets were identical except for 7 %
of energy (18.9 g in a diet of 10 MJ/day)
that was provided either by oleic acid, by
industrial trans fatty acids or by 9-cis,
11-trans CLA.
The effect of the CLA diet compared with
the oleic acid diet was 0.11 mm Hg (95 %
confidence interval: −1.27, 1.49) systolic and
−0.45 mm Hg (−1.63, 0.73) diastolic. Short-
term high intakes of 9-cis, 11-trans CLA do
not affect blood pressure in healthy volunteers.





Participants consumed under supervision
in random order 3.5 g/d of safflower oil
(control), a 50:50 mixture of 10-trans, 12-cis,
and 9-cis, 11-trans CLA:Clarinol G-80, and
9-cis, 11-trans isomer CLA
Compared with the control treatment, the CLA
treatments did not affect changes in body weight,
body composition, or blood lipids. In addition,
CLA did not affect the β-oxidation rate of fatty
















Table 1 Randomized clinical trials using CLA as intervention on putative benefits (Continued)
MICHISHITA et al., 2010
[67]
Forty-one healthy subjects Single-centre, randomized,
double-blind, placebo-
controlled trial
Subjects were randomized to receive either
placebo or one of three test supplements:
amino acid mixture 0.76 g/day; amino acid
mixture 1.52 g/day; or amino acid mixture
1.52 g/day coadministered with conjugated
linoleic acid 1.6 g/day and exercises for a period
of 12 weeks
The results suggest that ingestion of these
supplements might enhance the fat-burning
effects of exercise.




It was provided either by oleic acid, by
industrial trans fatty acids or by a mixture
of 80 % 9-cis, 11-trans and 20 % 10-trans,
12-cis CLA.
High intakes of an 80:20 mixture of 9-cis,
11-trans, and 10-trans, 12-cis CLA raise the
total to HDL cholesterol ratio in healthy
volunteers. The effect of CLA may be
somewhat less than that of industrial
trans fatty acids.
SLUIJS et al., 2010 [69] Four hundred and one Double-blind, randomized, placebo-
controlled and parallel-group trial
Subjects receive either 4 g CLA/d (2.5 g 9-cis,
11-trans CLA/d and 0.6 g 10-trans, 12-cis
CLA/d) or placebo supplements for 6 months
There was no effect of 9-cis, 11-trans CLA
supplementation on blood pressure, body
composition, insulin resistance, or
concentrations of lipid, glucose, and C-
reactive protein.
SYVERTSEN et al., 2007
[70]




Supplementation with either placebo
(olive oil) or CLA (Clarinol) for 6 months
CLA does not affect glucose metabolism
or insulin sensitivity in a population of















that CLA may reduce the percentage of fat in humans
over a 12-months period, besides increasing the lean
mass and not presenting any additional effect at doses
above 3.4 g of CLA per day. However since physical
training was performed at the same time as the CLA
was used, and the levels of exercise were different
among the groups, it was not possible to evaluate
whether the effect of the body changes was due to the
use of CLA, exercise, or the combination of both.
Gaullier et al. [11] performed a 24-month randomized,
double-blind placebo–controlled study, during which 6
capsules of gel were administered daily, totaling 4.5 g of
CLA. The authors observed that the CLA supplementa-
tion for this period in overweight adults is well tolerated,
and CLA reduces body fat in overweight humans and
can help maintain the initial fat and weight losses over
the long term [11].
As to gender, Santos-Zago et al. [20] showed the effect
of body fat reduction on healthy, eutrophic women who
consumed 3 kg of CLA per day, during 64 days. The re-
sults, however, were not significant, since CLA con-
sumption during this period did not alter the women’s
body composition [20]. On the other hand, individuals
with overweight and obesity, who consumed the amount
of 3.4 g of CLA per day for 12 weeks reduced their body
fat, as previously shown [10].
The responses to the different CLA isomers do not ap-
pear to present differences, although it was found that
the 10-trans, 12-cis isomer increased the concentration
of triglycerides and LDL cholesterol in a greater propor-
tion in healthy men compared to the 9-cis, 11-trans iso-
mer [21]. In a review study, obese men diagnosed with
metabolic syndrome used CLA for 4 weeks. The final re-
sult was a reduction of the abdominal circumference,
however other anthropometric measures did not
undergo a relevant change [37].
A randomized, double blind, placebo-controlled study
looked at the effects of CLA supplementation on body
composition and weight loss for 12 weeks, in individuals
with obesity or grade I obesity in the Chinese popula-
tion. Bioelectric impedance was the method used to
evaluate body composition changes during the study. In-
dividuals randomly received 1.7 g of 9-cis, 11-trans and
10-trans, 12-cis of CLA (n = 30) or placebo (n = 33) in
200 ml of sterilized milk twice a day. As a result it was
found that the group supplemented with CLA presented
a reduction of obesity and/or overweight besides other
benefits, without evidence of adverse effects [18].
Kim et al. [43] tested the supplementation of CLA
2.4 g/day CLA mixture (36.9 % of 9-cis, 11-trans and
37.9 % of 10-trans, 12-cis) as an antioxidant agent in
healthy overweight/obese Korean individuals. Eight
weeks of conjugated linoleic acid supplementation has
no effect on antioxidant status (plasma total radical-
trapping antioxidant potential, lipid peroxidation, lipid-
soluble antioxidant vitamin concentration, erythrocyte
antioxidant enzyme – superoxide dismutase, catalase,
glutathione peroxidase), and leukocyte DNA damage be-
tween the CLA, compared to placebo group.
Thirty-seven recreationally-trained women (mean
BMI = 25.1 ± 3.4) were randomized for three dietary in-
terventions: 1) a control diet (without changing their
usual dietary habits); 2) a high-protein, low-calorie diet
supplemented with protein gels (22 g of protein per
serving), encapsulated thermogenic (Burn®), multivitamin
(Balance®), and CLA (Tone®); and 3) a high-protein diet
with isocaloric placebo supplements. After three weeks,
women in the supplementation group had their body
weight and percentage of body fat (assessed by DEXA and
skinfolds) significantly decreased when compared to pla-
cebo or control diets. Despite these positive results, it is
noteworthy the fact that CLA was used concomitant to
other nutritional supplements, and it is thus difficult to as-
sess its effect individually on body adiposity [44].
In another study, 101 moderately obese subjects who
lost >8 % of their baseline body weight in a previous study
were subsequently assigned to a 1-year double-blind CLA
(3.4 g/day) or placebo (olive oil) supplementation regime
in combination with a modest hypocaloric diet. The au-
thors found no significant difference in body weight or
body fat regain (assessed by DEXA) between the treat-
ments; however, there was a significant increase in the
number of leukocytes with CLA supplementation [45].
Individuals with type 2 diabetes mellitus (T2DM)
using metformin (30 females and 26 males) were allo-
cated to an eight-week randomized trial and stratified by
sex, age and BMI into one of three groups: 1) 3 g CLA/
day (3 × 1 g capsules; a 50:50 isomer blend of 9-cis, 11-
trans and 10-trans, 12-cis CLA) plus 100 IU/day of vita-
min E; 2) 3 g CLA/day plus vitamin E placebo; 3) or
CLA placebo (soy bean oil) plus vitamin E placebo. By
the end of the study there were no significant differences
regarding body weight, body composition, glycemic
index and inflammatory profile among the three groups;
however, there was a trend toward an increase in malon-
dialdehyde levels (a marker of oxidative stress) and de-
crease in apoB100 (linked to HDL-cholesterol levels)
among those receiving CLA [46].
Thirty-five obese postmenopausal women with T2DM
were also randomized to receive safflower oil (8 g/day)
or CLA (6.4 g CLA isomers/day) in a 36-week random-
ized crossover trial (two 16-week diet periods separated
by a 4-week washout period). DEXA analysis was used
for the assessment of body composition. Supplementa-
tion with CLA reduced BMI and total adipose mass
without changing lean mass; in contrast, safflower oil re-
duced trunk adipose mass, increased lean mass and sig-
nificantly lowered fasting glucose. It is suggested that
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both oils have different effects on body composition in
obese women with T2DM who are not also on a weight-
loss diet or exercise plan [47].
Finally, a meta-analysis that included 7 clinical assays
in the final analysis for the purpose of evaluating the use
of CLA during a long time did not show significant re-
sults to support changes in the body composition when
using CLA for a longer period [48].
Recommended dose
Most of the studies were a mixture of the two predom-
inant isomers, 9-cis, 11-trans and 10-trans, 12-cis, in
equal proportions. The daily doses of CLA varied from
3 to 6 g/day, according to several studies and these
doses appear safe [49]. Although some studies indicate
that doses above 3.4 g/day would not have any add-
itional effect, they suggest that there is a very great
variation compared to the results due to different
doses, type of isomer, and evaluation of the body com-
position, which makes it difficult to compare different
studies [10, 18].
Adverse effects
Despite the positive effects of CLA supplementation on
some health-related parameters, there are a few reports
of possible adverse effects, mainly in rats and due to the
10-trans and 12-cis isomer. In the animal models pro-
carcinogenic effects and of increased production of pros-
taglandins attributed to CLA 10-trans and 12-cis have
been identified [50].
Other negative effect may be due to the increase in
the lipid oxidation products (isoprostanes), besides the
diminished leptin and greater probability of developing
insulin resistance [51]. Studies also show undesirable ef-
fects in human beings as increased levels of triglycerides
and LDL-cholesterol and reduction of the HDL levels,
suggesting a negative alteration in the serum lipids pro-
file [52]. Obese individuals also presented negative alter-
ations in the glucose metabolism with insulin resistance
in some studies [53, 54].
Conclusions
Despite studies on CLA supplementation for the pur-
pose of investigating changes in body composition and
other benefits, both in animals and in humans, they are
very discordant. The capacity of CLA to alter the body
composition positively by reducing the fat mass was
proved in experimental models, and, in some studies on
human beings. In fact, few studies have evaluated the
use of CLA alone or in combination with physical exer-
cise in humans, regarding changes in body composition.
Therefore, the clinical evidence appears to be insufficient
and not unanimous regarding the effects on body fat
reduction and major side effects have already been
described.
In this sense, the consumption of foods naturally
enriched with CLA (and not from supplementation) dur-
ing lifetime would be an alternative to reduce increased
adiposity. Besides, it could reduce de risk of other dis-
eases associated with obesity, since they would ensure
the beneficial effects on body composition and would
not add effects that are adverse to health.
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